中药经肝动脉介入治疗原发性肝癌的回顾与展望

Retrospect and Prospect of Interventional Therapy for Primary Hepatocellular Carcinama Through Hepatic Artery with Traditional Chinese Medicine

肝动脉化疗栓塞(TACE)是肝癌非手术治疗的首选方法,其近期疗效确切,但发热、肝功能损害等不良反应影响了生存期及生存质量。因此,研制低毒、高效的介入制剂,提高临床效果是近年来研究的热点。二十年来,中药经肝动脉介入治疗肝癌的研究取得了较大的成就,引起了学术界的高度关注。采用文献回顾的方法,对中药介入治疗肝癌的研究概况、存在的问题及其前景进行综述,以期寻找规律,为中药介入治疗肝癌标准化研究提供依据。

Transarterial ehemoembolization（TACE） has already become the first choice in the non-surgical treatment modality of liver cancer which has an exact short-term effects, but the adverse effects such as fever and functional lesion of liver affect survival time and quality of life. So it is important to develop low toxicity, high efficiency interventional preparation to improve clinical effects. In the past two decades, interventional therapy for primary hepatoeellular eareinama through hepatic artery with traditional Chinese medicine has made great achievements, which has attracted the attention of domestic academe. Retrospective research method was conducted in this paper to find out the existing problems and prospects of interventional treatment with traditional Chinese medicine for standardization treatment of Chinese medicine.